Jenna L. Terebetski
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Receptor Mechanisms and Signaling, Diabetes Treatment and Management, Drug Solubulity and Delivery Systems, Neuropeptides and Animal Physiology, Analytical Methods in Pharmaceuticals
Most-Cited Works
- → Discovery of MK-4409, a Novel Oxazole FAAH Inhibitor for the Treatment of Inflammatory and Neuropathic Pain(2014)41 cited
- → Discovery of MK-3168: A PET Tracer for Imaging Brain Fatty Acid Amide Hydrolase(2013)36 cited
- → Combining ibuprofen sodium with cellulosic polymers: A deep dive into mechanisms of prolonged supersaturation(2014)26 cited
- → Combined Use of Crystalline Sodium Salt and Polymeric Precipitation Inhibitors to Improve Pharmacokinetic Profile of Ibuprofen through Supersaturation(2014)25 cited
- → Discovery and Optimization of a Novel Triazole Series of GPR142 Agonists for the Treatment of Type 2 Diabetes(2016)15 cited
- → Design of Potent and Orally Active GPR119 Agonists for the Treatment of Type II Diabetes(2015)13 cited
- → Discovery of phenyl acetamides as potent and selective GPR119 agonists(2017)12 cited
- → Inhaled Formulation and Device selection: Bridging the Gap Between Preclinical Species and first-in-human Studies(2018)12 cited
- → Using [2H]water to quantify the contribution of de novo palmitate synthesis in plasma: enabling back-to-back studies(2018)12 cited
- → Fragment-based lead discovery of a novel class of small molecule antagonists of neuropeptide B/W receptor subtype 1 (GPR7)(2020)11 cited